株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血漿製剤の世界市場 (2015〜2019年)

Global Plasma Therapeutics Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 336931
出版日 ページ情報 英文 71 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
血漿製剤の世界市場 (2015〜2019年) Global Plasma Therapeutics Market 2015-2019
出版日: 2015年08月05日 ページ情報: 英文 71 Pages
概要

血漿は血液中の成分の一つで、血液細胞やその他の成分を輸送する手段となっています。また、水分や塩分・酵素、栄養素、ホルモンなどの物質を体内各所に運ぶという役割も果たしています。血漿には免疫グロブリンや凝固因子、ある部門などの成分が含まれており、様々な疾患の治癒に役立っています。血漿は血液から、血漿分離交換法と呼ばれる手段を用いて分離されます。血漿製剤は様々な難病や遺伝子疾患 (免疫不全、肺障害、神経障害、ショック症、外傷、肝硬変など)、感染症 (破傷風、肝炎、狂犬病など) の治療に用いられています。世界の血漿製剤市場は2014〜2019年にかけて、12.10%の年平均成長率 (CAGR) で成長する見通しです。

当レポートでは、世界の血漿製剤 (血漿由来の治療薬) の市場について分析し、製品の概要・規制環境や基本的な市場構造、市場規模の動向 (今後5年間の予測値)、製品別・疾患別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブサマリー

  • 分析結果の概略

第2章 分析範囲

  • 分析概要
  • 主要ベンダーの製品

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略

第5章 血漿製剤の概要

  • 血漿の成分
  • 血漿製剤の生成過程
  • 血漿の臨床利用
  • 血漿製剤のコスト構造

第6章 血漿製剤の関連規制

  • 規制当局

第7章 市場環境

  • 市場概要
  • 市場規模とその予測
  • ファイブフォース分析

第8章 市場の区分:血漿分画製剤別

  • ヒトアルブミン
  • 血漿由来の血液凝固因子
  • 免疫グロブリン
  • 高度免疫グロブリン
  • A1PI (α1プロテイナーゼ阻害薬)
  • 世界のヒトアルブミン市場 (今後6年間分)
  • 世界の免疫グロブリン市場 (今後6年間分)
  • 世界のA1PI市場 (今後6年間分)

第9章 疾患の種類別の市場区分

  • 凝固障害
  • 免疫障害
  • AATD (α1抗トリプシン欠損症)
  • その他

第10章 地域区分

第11章 市場成長の促進要因

第12章 促進要因とその影響力

第13章 市場の課題

第14章 促進要因・課題の影響力

第15章 市場の動向

第16章 ベンダー環境

  • 競争シナリオ
  • 市場シェア分析
  • その他の有力ベンダー

第17章 主要ベンダーの分析

  • Baxter International Inc.
  • CSL Behring
  • Grifols
  • Octapharma

第18章 付録

  • 略語集

図表一覧

目次
Product Code: IRTNTR6802

About plasma and plasma therapeutics

Plasma, pale yellow in color, is the component of the blood. It acts as a medium of transportation for the blood cells and other components. It carries salts and enzymes along with water and also transports nutrients, hormones, and other substances to the different parts of the body. Plasma contains immunoglobulins, clotting factors, albumin, and other components that can be used for the treatment of various diseases. The separation of plasma from the blood is done by a process known as plasmapheresis. Plasma therapeutics are utilized in the treatment of rare, life-threatening, chronic, and genetic diseases, such as immune deficiencies, pulmonary disorders, neurological disorders, shock and trauma, liver cirrhosis, and infectious diseases such as tetanus, hepatitis, and rabies.

Technavio's analysts forecast the global plasma therapeutics market to grow at a CAGR of 12.10% over the period 2014-2019.

Covered in this report

The report covers the present scenario and the growth prospects of the global plasma therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded therapies derived from the various fractions of plasma such as albumin, immunoglobulins, coagulation factors, hyperimmune globulins, and A1PI.

Technavio's report, Global Plasma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global plasma therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Baxter
  • CSL Behring
  • Grifols Therapeutics
  • Octapharma

Other Prominent Vendors

  • Abeona Therapeutics
  • ADMA Biologics
  • Amag Pharmaceuticals
  • Antares Pharma
  • BioDelivery Sciences
  • Bio Products Laboratory
  • Biota Pharmaceuticals
  • Biotest Pharmaceuticals
  • China Biologic Products
  • Depomed
  • Emergent BioSolutions
  • Ethicon
  • Flamel Technologies
  • Kamada
  • Kedrion
  • King Pharmaceuticals
  • Nektar Therapeutics
  • OMRIX Biopharmaceuticals
  • ProMetic Life Sciences
  • Rockwell Medical
  • The Medicines
  • ZymoGenetics

Key market driver

  • Growing demand for IVIG therapies
  • For a full, detailed list, view our report

Key market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Key market trend

  • Patient assistance programs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01:Executive summary

  • Highlights

PART 02:Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03:Market research methodology

  • Research methodology
  • Economic indicators

PART 04:Introduction

  • Key market highlights

PART 05:Plasma therapeutics: An overview:

  • Components of blood plasma
  • Process to derive plasma therapeutics
  • Clinical uses of plasma
  • Cost structure of plasma therapeutics

PART 06:Regulation of plasma therapeutics

  • Regulatory authorities

PART 07:Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08:Market segmentation by fractionation products of plasma

  • Human albumin
  • Plasma derived coagulation factors
  • Immunoglobulins
  • Hyperimmune globulins
  • A1PI
  • Global human albumin market 2014-2019
  • Global immunoglobulins market 2014-2019
  • Global A1PI market 2014-2019

PART 09:Market segmentation by disease type

  • Clotting disorders
  • Immune disorders
  • AATD
  • Others

PART 10:Geographical segmentation

PART 11:Market drivers

PART 12:Impact of drivers

PART 13:Market challenges

PART 14:Impact of drivers and challenges

PART 15:Market trends

PART 16:Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 17:Key vendor analysis

  • Baxter International Inc.
  • CSL Behring
  • Grifols
  • Octapharma

PART 18:Appendix

  • List of abbreviation

List of Exhibits:

  • Exhibit 01: Product offerings
  • Exhibit 02: Composition of blood
  • Exhibit 03: Composition of plasma
  • Exhibit 04: Total collection of plasma in US 2010-2014 (in liters)
  • Exhibit 05: Projected fractionation capacity of manufacturing units in US and EU (millions of liter/annum)
  • Exhibit 06: Process of procurement and manufacturing of plasma therapeutics
  • Exhibit 07: Regulatory policies of plasma protein therapy lifecycle
  • Exhibit 08: Global plasma therapeutics market 2014-2019 ($ billions)
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global plasma therapeutics market segment by fractionation products of plasma
  • Exhibit 11: Global human albumin market 2014-2019 ($ millions)
  • Exhibit 12: Key performance indicators of global albumin market
  • Exhibit 13: Global immunoglobulins market 2014-2019 ($ millions)
  • Exhibit 14: Key performance indicators of global immunoglobulin market
  • Exhibit 15: Global A1PI market 2014-2019 ($ millions)
  • Exhibit 16: Key performance indicators of global A1PI market
  • Exhibit 17: Global plasma therapeutics market segment by disease type
  • Exhibit 18: Segmentation of global plasma therapeutics market by geography 2014
  • Exhibit 19: Drivers of global plasma therapeutics market
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Challenges of global plasma therapeutics market
  • Exhibit 22: Impact of drivers and challenges
  • Exhibit 23: Global plasma therapeutics market share analysis 2014
  • Exhibit 24: YoY growth and revenue generated by plasma therapeutics 2011-2014 ($ millions)
  • Exhibit 25: YoY growth and revenue generate 2011-2014 ($ millions)
  • Exhibit 26: YoY growth and revenue of bioscience division 2011-2014 ($ millions)
  • Exhibit 27: Share of revenue by different divisions in 2014
  • Exhibit 28: YoY growth and revenue of plasma therapeutics 2011-2014 ($ millions)
  • Exhibit 29: Baxter International Inc. : Business segmentation
  • Exhibit 30: Baxter International Inc.: Revenue by business segmentation 2013
  • Exhibit 31: Baxter International Inc.: Revenue by geographical segmentation 2013
  • Exhibit 32: CSL Behring: Therapeutic areas segmentation 2013
  • Exhibit 33: CSL Behring: Product portfolio
  • Exhibit 34: CSL Behring: Geographical segmentation by revenue 2013
  • Exhibit 35: Grifols: Business segmentation by revenue 2013
  • Exhibit 36: Grifols: Business segmentation by revenue 2012 and 2013 ($ billions)
  • Exhibit 37: Grifols: Geographical segmentation by revenue 2013
  • Exhibit 38: Octapharma: Product offerings
Back to Top